Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network

Matthew T. Aliota, Leda Bassit, Shelton S. Bradrick, Bryan Cox, Mariano A. Garcia-Blanco, Christina Gavegnano, Thomas C. Friedrich, Thaddeus G. Golos, Diane Griffin, Andrew D. Haddow, Esper G. Kallas, Uriel Kitron, Marc Lecuit, Diogo M. Magnani, Caroline Marrs, Natalia Mercer, Edward McSweegan, Lisa F.P. Ng, David H. O'Connor, Jorge E. OsorioGuilherme S. Ribeiro, Michael Ricciardi, Shannan L. Rossi, George Saade, Raymond F. Schinazi, Geraldine O. Schott-Lerner, Chao Shan, Pei Yong Shi, David I. Watkins, Nikos Vasilakis, Scott C. Weaver

Research output: Contribution to journalReview article

Abstract

In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV-induced disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of ZIKV in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary ZIKV-induced disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic.

Original languageEnglish (US)
Pages (from-to)223-246
Number of pages24
JournalAntiviral Research
Volume144
DOIs
StatePublished - Aug 1 2017

Fingerprint

Viruses
Routine Diagnostic Tests
Antiviral Agents
Mosquito Control
Active Immunotherapy
Infectious Disease Transmission
Laboratory Animals
Pandemics
Disease Outbreaks
Vaccines
Public Health
Mothers
Research
Zika Virus Infection
Zika Virus
Therapeutics

Keywords

  • Antiviral therapy
  • Arbovirus
  • Congenital manifestations
  • Maternal-fetal transmission
  • Vaccines
  • Zika virus

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Cite this

Aliota, M. T., Bassit, L., Bradrick, S. S., Cox, B., Garcia-Blanco, M. A., Gavegnano, C., ... Weaver, S. C. (2017). Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network. Antiviral Research, 144, 223-246. https://doi.org/10.1016/j.antiviral.2017.06.001

Zika in the Americas, year 2 : What have we learned? What gaps remain? A report from the Global Virus Network. / Aliota, Matthew T.; Bassit, Leda; Bradrick, Shelton S.; Cox, Bryan; Garcia-Blanco, Mariano A.; Gavegnano, Christina; Friedrich, Thomas C.; Golos, Thaddeus G.; Griffin, Diane; Haddow, Andrew D.; Kallas, Esper G.; Kitron, Uriel; Lecuit, Marc; Magnani, Diogo M.; Marrs, Caroline; Mercer, Natalia; McSweegan, Edward; Ng, Lisa F.P.; O'Connor, David H.; Osorio, Jorge E.; Ribeiro, Guilherme S.; Ricciardi, Michael; Rossi, Shannan L.; Saade, George; Schinazi, Raymond F.; Schott-Lerner, Geraldine O.; Shan, Chao; Shi, Pei Yong; Watkins, David I.; Vasilakis, Nikos; Weaver, Scott C.

In: Antiviral Research, Vol. 144, 01.08.2017, p. 223-246.

Research output: Contribution to journalReview article

Aliota, MT, Bassit, L, Bradrick, SS, Cox, B, Garcia-Blanco, MA, Gavegnano, C, Friedrich, TC, Golos, TG, Griffin, D, Haddow, AD, Kallas, EG, Kitron, U, Lecuit, M, Magnani, DM, Marrs, C, Mercer, N, McSweegan, E, Ng, LFP, O'Connor, DH, Osorio, JE, Ribeiro, GS, Ricciardi, M, Rossi, SL, Saade, G, Schinazi, RF, Schott-Lerner, GO, Shan, C, Shi, PY, Watkins, DI, Vasilakis, N & Weaver, SC 2017, 'Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network', Antiviral Research, vol. 144, pp. 223-246. https://doi.org/10.1016/j.antiviral.2017.06.001
Aliota, Matthew T. ; Bassit, Leda ; Bradrick, Shelton S. ; Cox, Bryan ; Garcia-Blanco, Mariano A. ; Gavegnano, Christina ; Friedrich, Thomas C. ; Golos, Thaddeus G. ; Griffin, Diane ; Haddow, Andrew D. ; Kallas, Esper G. ; Kitron, Uriel ; Lecuit, Marc ; Magnani, Diogo M. ; Marrs, Caroline ; Mercer, Natalia ; McSweegan, Edward ; Ng, Lisa F.P. ; O'Connor, David H. ; Osorio, Jorge E. ; Ribeiro, Guilherme S. ; Ricciardi, Michael ; Rossi, Shannan L. ; Saade, George ; Schinazi, Raymond F. ; Schott-Lerner, Geraldine O. ; Shan, Chao ; Shi, Pei Yong ; Watkins, David I. ; Vasilakis, Nikos ; Weaver, Scott C. / Zika in the Americas, year 2 : What have we learned? What gaps remain? A report from the Global Virus Network. In: Antiviral Research. 2017 ; Vol. 144. pp. 223-246.
@article{551dfb77c41c475099f39eb9d3d8f8fa,
title = "Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network",
abstract = "In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV-induced disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of ZIKV in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary ZIKV-induced disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic.",
keywords = "Antiviral therapy, Arbovirus, Congenital manifestations, Maternal-fetal transmission, Vaccines, Zika virus",
author = "Aliota, {Matthew T.} and Leda Bassit and Bradrick, {Shelton S.} and Bryan Cox and Garcia-Blanco, {Mariano A.} and Christina Gavegnano and Friedrich, {Thomas C.} and Golos, {Thaddeus G.} and Diane Griffin and Haddow, {Andrew D.} and Kallas, {Esper G.} and Uriel Kitron and Marc Lecuit and Magnani, {Diogo M.} and Caroline Marrs and Natalia Mercer and Edward McSweegan and Ng, {Lisa F.P.} and O'Connor, {David H.} and Osorio, {Jorge E.} and Ribeiro, {Guilherme S.} and Michael Ricciardi and Rossi, {Shannan L.} and George Saade and Schinazi, {Raymond F.} and Schott-Lerner, {Geraldine O.} and Chao Shan and Shi, {Pei Yong} and Watkins, {David I.} and Nikos Vasilakis and Weaver, {Scott C.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.antiviral.2017.06.001",
language = "English (US)",
volume = "144",
pages = "223--246",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - Zika in the Americas, year 2

T2 - What have we learned? What gaps remain? A report from the Global Virus Network

AU - Aliota, Matthew T.

AU - Bassit, Leda

AU - Bradrick, Shelton S.

AU - Cox, Bryan

AU - Garcia-Blanco, Mariano A.

AU - Gavegnano, Christina

AU - Friedrich, Thomas C.

AU - Golos, Thaddeus G.

AU - Griffin, Diane

AU - Haddow, Andrew D.

AU - Kallas, Esper G.

AU - Kitron, Uriel

AU - Lecuit, Marc

AU - Magnani, Diogo M.

AU - Marrs, Caroline

AU - Mercer, Natalia

AU - McSweegan, Edward

AU - Ng, Lisa F.P.

AU - O'Connor, David H.

AU - Osorio, Jorge E.

AU - Ribeiro, Guilherme S.

AU - Ricciardi, Michael

AU - Rossi, Shannan L.

AU - Saade, George

AU - Schinazi, Raymond F.

AU - Schott-Lerner, Geraldine O.

AU - Shan, Chao

AU - Shi, Pei Yong

AU - Watkins, David I.

AU - Vasilakis, Nikos

AU - Weaver, Scott C.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV-induced disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of ZIKV in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary ZIKV-induced disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic.

AB - In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV-induced disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of ZIKV in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary ZIKV-induced disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic.

KW - Antiviral therapy

KW - Arbovirus

KW - Congenital manifestations

KW - Maternal-fetal transmission

KW - Vaccines

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85021325699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021325699&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2017.06.001

DO - 10.1016/j.antiviral.2017.06.001

M3 - Review article

C2 - 28595824

AN - SCOPUS:85021325699

VL - 144

SP - 223

EP - 246

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -